Cargando…
Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’
BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, E...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953858/ https://www.ncbi.nlm.nih.gov/pubmed/31923216 http://dx.doi.org/10.1371/journal.pone.0226892 |
_version_ | 1783486692730077184 |
---|---|
author | Thiruganasambandamoorthy, Venkatesh Stiell, Ian G. Chaudry, Hina Mukarram, Muhammad Booth, Ronald A. Toarta, Cristian Hebert, Guy Beanlands, Robert S. Wells, George A. Nemnom, Marie-Joe Taljaard, Monica |
author_facet | Thiruganasambandamoorthy, Venkatesh Stiell, Ian G. Chaudry, Hina Mukarram, Muhammad Booth, Ronald A. Toarta, Cristian Hebert, Guy Beanlands, Robert S. Wells, George A. Nemnom, Marie-Joe Taljaard, Monica |
author_sort | Thiruganasambandamoorthy, Venkatesh |
collection | PubMed |
description | BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, Electrocardiogram (ECG), Age, Risk factors, Troponin] score to the pathway. METHODS: We prospectively enrolled adults with NSTEMI symptoms at two-large emergency departments (EDs) over 32-months. Patients with STEMI, unstable angina and one cTn were excluded. We collected baseline characteristics, Siemens Vista conventional cTnI at 0, 3 or 6-hours after ED presentation; HEART score predictors; disposition and ED length of stay (LOS). Adjudicated primary outcome was 15-day MACE (acute MI, revascularization, or death due to cardiac ischemia/unknown cause). We analyzed multiples of 99th percentile cut-off cTnI values (45, 100 and 250ng/L). RESULTS: 1,683 patients (mean age 64.7 years; 55.3% female; median LOS 7-hours; 88 patients with 15-day MACE) were included. 1,346 (80.0%) patients with both cTnI≤45 ng/L; and 155 (9.2%) of the 213 patients with one value≥100ng/L but both<250ng/L or ≤20% change did not suffer MACE. Among 124 patients (7.4%) with one of the two values>45ng/L but<100ng/L based on 3 or 6-hour cTnI, one patient with absolute change<10ng/L and 6 of the 19 patients with≥20ng/L were diagnosed with NSTEMI (patients with Δ10-19ng/L between first and second cTnI had third one at 6-hours). Based on the results, we developed the Ottawa Troponin Pathway (OTP) with a 98.9% sensitivity (95% CI 93.8–100%) and 94.6% specificity (95% CI 93.3–95.6%). Addition of the HEART score improved the sensitivity to 100% (95% CI 95.9–100%) and decreased the specificity to 26.5% (95% CI 24.3–28.7%). CONCLUSION: The OTP with conventional cTnI 3-hours apart, should lead to better NSTEMI identification particularly those with values >99th percentile, standardize management and reduce the ED LOS. |
format | Online Article Text |
id | pubmed-6953858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69538582020-01-21 Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ Thiruganasambandamoorthy, Venkatesh Stiell, Ian G. Chaudry, Hina Mukarram, Muhammad Booth, Ronald A. Toarta, Cristian Hebert, Guy Beanlands, Robert S. Wells, George A. Nemnom, Marie-Joe Taljaard, Monica PLoS One Research Article BACKGROUND: Serial conventional cardiac troponin (cTn) measurements 6–9 hours apart are recommended for non-ST-elevation MI (NSTEMI) diagnosis. We sought to develop a pathway with 3-hour changes for major adverse cardiac event (MACE) identification and assess the added value of the HEART [History, Electrocardiogram (ECG), Age, Risk factors, Troponin] score to the pathway. METHODS: We prospectively enrolled adults with NSTEMI symptoms at two-large emergency departments (EDs) over 32-months. Patients with STEMI, unstable angina and one cTn were excluded. We collected baseline characteristics, Siemens Vista conventional cTnI at 0, 3 or 6-hours after ED presentation; HEART score predictors; disposition and ED length of stay (LOS). Adjudicated primary outcome was 15-day MACE (acute MI, revascularization, or death due to cardiac ischemia/unknown cause). We analyzed multiples of 99th percentile cut-off cTnI values (45, 100 and 250ng/L). RESULTS: 1,683 patients (mean age 64.7 years; 55.3% female; median LOS 7-hours; 88 patients with 15-day MACE) were included. 1,346 (80.0%) patients with both cTnI≤45 ng/L; and 155 (9.2%) of the 213 patients with one value≥100ng/L but both<250ng/L or ≤20% change did not suffer MACE. Among 124 patients (7.4%) with one of the two values>45ng/L but<100ng/L based on 3 or 6-hour cTnI, one patient with absolute change<10ng/L and 6 of the 19 patients with≥20ng/L were diagnosed with NSTEMI (patients with Δ10-19ng/L between first and second cTnI had third one at 6-hours). Based on the results, we developed the Ottawa Troponin Pathway (OTP) with a 98.9% sensitivity (95% CI 93.8–100%) and 94.6% specificity (95% CI 93.3–95.6%). Addition of the HEART score improved the sensitivity to 100% (95% CI 95.9–100%) and decreased the specificity to 26.5% (95% CI 24.3–28.7%). CONCLUSION: The OTP with conventional cTnI 3-hours apart, should lead to better NSTEMI identification particularly those with values >99th percentile, standardize management and reduce the ED LOS. Public Library of Science 2020-01-10 /pmc/articles/PMC6953858/ /pubmed/31923216 http://dx.doi.org/10.1371/journal.pone.0226892 Text en © 2020 Thiruganasambandamoorthy et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Thiruganasambandamoorthy, Venkatesh Stiell, Ian G. Chaudry, Hina Mukarram, Muhammad Booth, Ronald A. Toarta, Cristian Hebert, Guy Beanlands, Robert S. Wells, George A. Nemnom, Marie-Joe Taljaard, Monica Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title | Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title_full | Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title_fullStr | Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title_full_unstemmed | Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title_short | Use of conventional cardiac troponin assay for diagnosis of non-ST-elevation myocardial infarction: ‘The Ottawa Troponin Pathway’ |
title_sort | use of conventional cardiac troponin assay for diagnosis of non-st-elevation myocardial infarction: ‘the ottawa troponin pathway’ |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953858/ https://www.ncbi.nlm.nih.gov/pubmed/31923216 http://dx.doi.org/10.1371/journal.pone.0226892 |
work_keys_str_mv | AT thiruganasambandamoorthyvenkatesh useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT stielliang useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT chaudryhina useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT mukarrammuhammad useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT boothronalda useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT toartacristian useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT hebertguy useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT beanlandsroberts useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT wellsgeorgea useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT nemnommariejoe useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway AT taljaardmonica useofconventionalcardiactroponinassayfordiagnosisofnonstelevationmyocardialinfarctiontheottawatroponinpathway |